Chemotherapy-Induced Nausea and Vomiting Drugs Market by Major Drugs (Marketed Drugs, and Pipeline Drugs) and Forecast 2017-2021

Chemotherapy-Induced Nausea and Vomiting Drugs Market by Major Drugs (Marketed Drugs, and Pipeline Drugs) and Forecast 2017-2021

Nausea and vomiting are serious side effects of cancer chemotherapy that can cause significant negative impacts on patients’ quality of life and on their ability to tolerate and comply with therapy. Chemotherapy-induced Nausea and Vomiting (CINV) can be defined as acute CINV, delayed CINV or anticipatory CINV. Antiemetic agents are the most common intervention in the management of treatment-related nausea and vomiting (N&V) that completely block the peripheral neuroreceptors and the chemoreceptor trigger zone (CTZ) that are known to contain receptors for serotonin, histamine (H1 and H2), dopamine, acetylcholine, opioids, and numerous other endogenous neurotransmitters.

The global chemotherapy-induced nausea and vomiting drugs market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021).

The global chemotherapy-induced nausea and vomiting drugs market segmentation is based on major drugs (Marketed Drugs, and Pipeline Drugs). The global chemotherapy-induced nausea and vomiting drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

The currently available chemotherapy-induced nausea and vomiting drugs do not effectively address the symptoms of this condition compared to pipeline drugs, as demonstrated in the clinical studies. Aloxi (palonosetron), Zofran generic (ondansetron), Kytril generic (granisetron), Emend (aprepitant) and Akynzeo (netupitantpalonosetron FDC) are currently approved marketed CINV drugs, while the major pipeline drugs such as SUSTOL (extended release generic granisetron) and rolapitant are expected to be approved in the near future. The stringent regulatory approval process and high cost associated with new drug discovery and development are also expected to affect market growth during the forecast period.

Major players operating in the global chemotherapy-induced nausea and vomiting drugs market and included in this report are GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc. and Tesaro, Inc.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Chemotherapy-induced Nausea and Vomiting Drugs Market

1. Drug Type
1.1 Marketed Drugs
1.1.1 Aloxi(palonosetron)
1.1.2 Zofran Generic (ondansetron)
1.1.3 Kytril generic (granisetron)
1.1.4 Emend (aprepitant)
1.1.5 Akynzeo (Netupitant-palonosetron FDC)
1.2 Pipeline Drugs
1.2.1 SUSTOL (Granisetron injection – extended release)
1.2.2 Rolapitant

2. Geography (Region, Country)
2.1 North America (U.S., Canada)
2.2 Latin America (Brazil, Mexico, Rest of LA)
2.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4 Asia Pacific (Japan, China, India, Rest of APAC)
2.5 Rest of the World

3. Company Profiles
3.1 GlaxoSmithKline plc
3.2 Helsinn Holding S.A.
3.3 Heron Therapeutics, Inc.
3.4 Merck & Co., Inc.
3.5 Tesaro, Inc.

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*